Stem definition | Drug id | CAS RN |
---|---|---|
4746 | 19171-19-8 |
Dose | Unit | Route |
---|---|---|
3 | mg | O |
None
Date | Agency | Company | Orphan |
---|---|---|---|
Feb. 8, 2013 | FDA | CELGENE | |
March 26, 2015 | PMDA | CELGENE K.K. |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Plasma cell myeloma | 6812.63 | 21.46 | 2354 | 57863 | 44292 | 56187558 |
Death | 1865.04 | 21.46 | 2044 | 58173 | 339382 | 55892468 |
White blood cell count decreased | 1467.55 | 21.46 | 1154 | 59063 | 124836 | 56107014 |
Full blood count decreased | 1428.28 | 21.46 | 629 | 59588 | 22720 | 56209130 |
Pneumonia | 1352.56 | 21.46 | 1900 | 58317 | 405198 | 55826652 |
Neuropathy peripheral | 867.13 | 21.46 | 783 | 59434 | 102110 | 56129740 |
Laboratory test abnormal | 819.83 | 21.46 | 438 | 59779 | 24257 | 56207593 |
Neutropenia | 767.79 | 21.46 | 894 | 59323 | 157273 | 56074577 |
Fatigue | 473.60 | 21.46 | 1873 | 58344 | 786679 | 55445171 |
Thrombosis | 426.31 | 21.46 | 414 | 59803 | 59013 | 56172837 |
Platelet count decreased | 388.31 | 21.46 | 522 | 59695 | 105861 | 56125989 |
Rheumatoid arthritis | 388.14 | 21.46 | 4 | 60213 | 382600 | 55849250 |
Neutrophil count decreased | 385.60 | 21.46 | 362 | 59855 | 49460 | 56182390 |
Unevaluable event | 373.88 | 21.46 | 349 | 59868 | 47338 | 56184512 |
Constipation | 371.01 | 21.46 | 725 | 59492 | 201218 | 56030632 |
Plasma cell myeloma recurrent | 290.47 | 21.46 | 110 | 60107 | 2664 | 56229186 |
Adverse drug reaction | 282.04 | 21.46 | 348 | 59869 | 64784 | 56167066 |
Condition aggravated | 272.32 | 21.46 | 27 | 60190 | 344871 | 55886979 |
COVID-19 | 256.60 | 21.46 | 357 | 59860 | 74701 | 56157149 |
Plasmacytoma | 248.18 | 21.46 | 95 | 60122 | 2371 | 56229479 |
Influenza | 237.37 | 21.46 | 391 | 59826 | 94870 | 56136980 |
Human chorionic gonadotropin increased | 216.88 | 21.46 | 74 | 60143 | 1312 | 56230538 |
Muscle spasms | 195.74 | 21.46 | 445 | 59772 | 136926 | 56094924 |
Drug ineffective | 174.49 | 21.46 | 462 | 59755 | 918527 | 55313323 |
Product dose omission issue | 157.30 | 21.46 | 529 | 59688 | 204224 | 56027626 |
Tremor | 152.59 | 21.46 | 374 | 59843 | 120715 | 56111135 |
Drug interaction | 147.07 | 21.46 | 24 | 60193 | 209731 | 56022119 |
Nasopharyngitis | 145.78 | 21.46 | 543 | 59674 | 220416 | 56011434 |
Bronchitis | 137.38 | 21.46 | 343 | 59874 | 111968 | 56119882 |
Drug hypersensitivity | 133.17 | 21.46 | 64 | 60153 | 275141 | 55956709 |
Asthenia | 132.00 | 21.46 | 718 | 59499 | 342255 | 55889595 |
Urinary tract infection | 125.09 | 21.46 | 549 | 59668 | 239964 | 55991886 |
Infusion related reaction | 123.90 | 21.46 | 35 | 60182 | 208896 | 56022954 |
Diarrhoea | 122.58 | 21.46 | 1128 | 59089 | 637379 | 55594471 |
Cytopenia | 116.57 | 21.46 | 91 | 60126 | 9664 | 56222186 |
Peripheral swelling | 113.95 | 21.46 | 525 | 59692 | 234201 | 55997649 |
Arthralgia | 112.56 | 21.46 | 230 | 59987 | 501439 | 55730411 |
Full blood count increased | 111.92 | 21.46 | 41 | 60176 | 902 | 56230948 |
Injection site pain | 111.21 | 21.46 | 3 | 60214 | 117115 | 56114735 |
Renal disorder | 108.90 | 21.46 | 146 | 60071 | 29459 | 56202391 |
Light chain analysis increased | 104.04 | 21.46 | 41 | 60176 | 1108 | 56230742 |
Product use in unapproved indication | 103.53 | 21.46 | 14 | 60203 | 140808 | 56091042 |
Cardiac disorder | 103.12 | 21.46 | 180 | 60037 | 45707 | 56186143 |
Treatment failure | 102.02 | 21.46 | 28 | 60189 | 170364 | 56061486 |
Thrombocytopenia | 96.66 | 21.46 | 343 | 59874 | 135881 | 56095969 |
Product use issue | 96.66 | 21.46 | 39 | 60178 | 186002 | 56045848 |
Anaemia | 96.09 | 21.46 | 550 | 59667 | 266961 | 55964889 |
Red blood cell count decreased | 94.74 | 21.46 | 153 | 60064 | 36464 | 56195386 |
Glossodynia | 91.36 | 21.46 | 25 | 60192 | 152433 | 56079417 |
Therapeutic product effect decreased | 87.25 | 21.46 | 36 | 60181 | 169416 | 56062434 |
Back pain | 86.04 | 21.46 | 489 | 59728 | 236681 | 55995169 |
Wound | 82.72 | 21.46 | 23 | 60194 | 138781 | 56093069 |
Atrial fibrillation | 79.65 | 21.46 | 277 | 59940 | 108620 | 56123230 |
Abdominal pain | 78.39 | 21.46 | 97 | 60120 | 258708 | 55973142 |
Hepatic enzyme increased | 78.14 | 21.46 | 43 | 60174 | 171341 | 56060509 |
Dizziness | 77.20 | 21.46 | 675 | 59542 | 375465 | 55856385 |
Discomfort | 76.47 | 21.46 | 28 | 60189 | 141733 | 56090117 |
Psoriasis | 76.40 | 21.46 | 6 | 60211 | 92686 | 56139164 |
Therapeutic product effect incomplete | 74.56 | 21.46 | 12 | 60205 | 106019 | 56125831 |
Overdose | 74.36 | 21.46 | 12 | 60205 | 105818 | 56126032 |
Cataract | 72.84 | 21.46 | 166 | 60051 | 51081 | 56180769 |
Infection | 72.71 | 21.46 | 413 | 59804 | 199793 | 56032057 |
Hip fracture | 71.55 | 21.46 | 114 | 60103 | 26859 | 56204991 |
Pain | 71.03 | 21.46 | 418 | 59799 | 662766 | 55569084 |
Haemoglobin decreased | 66.44 | 21.46 | 302 | 59915 | 133835 | 56098015 |
Sepsis | 65.69 | 21.46 | 310 | 59907 | 139530 | 56092320 |
Bone pain | 65.25 | 21.46 | 157 | 60060 | 50028 | 56181822 |
Helicobacter infection | 62.52 | 21.46 | 4 | 60213 | 73264 | 56158586 |
Tooth disorder | 62.35 | 21.46 | 104 | 60113 | 25449 | 56206401 |
Blood test abnormal | 61.30 | 21.46 | 72 | 60145 | 12712 | 56219138 |
Full blood count abnormal | 61.00 | 21.46 | 105 | 60112 | 26357 | 56205493 |
Pulmonary thrombosis | 59.44 | 21.46 | 57 | 60160 | 7980 | 56223870 |
Immune system disorder | 58.57 | 21.46 | 59 | 60158 | 8768 | 56223082 |
Impaired healing | 58.48 | 21.46 | 11 | 60206 | 86830 | 56145020 |
Mobility decreased | 57.86 | 21.46 | 17 | 60200 | 98974 | 56132876 |
Rash | 57.59 | 21.46 | 791 | 59426 | 492256 | 55739594 |
Plasma cell leukaemia | 56.90 | 21.46 | 27 | 60190 | 1156 | 56230694 |
Headache | 56.30 | 21.46 | 359 | 59858 | 558685 | 55673165 |
Off label use | 55.58 | 21.46 | 358 | 59859 | 555822 | 55676028 |
Fall | 54.42 | 21.46 | 603 | 59614 | 356907 | 55874943 |
Illness | 53.78 | 21.46 | 116 | 60101 | 34395 | 56197455 |
Respiratory syncytial virus infection | 50.70 | 21.46 | 44 | 60173 | 5417 | 56226433 |
Deep vein thrombosis | 50.47 | 21.46 | 189 | 60028 | 76788 | 56155062 |
Renal failure | 50.45 | 21.46 | 243 | 59974 | 110257 | 56121593 |
Abdominal discomfort | 50.21 | 21.46 | 142 | 60075 | 277132 | 55954718 |
Wrong technique in product usage process | 50.16 | 21.46 | 3 | 60214 | 58165 | 56173685 |
Multiple allergies | 50.14 | 21.46 | 59 | 60158 | 10437 | 56221413 |
Hypercalcaemia | 49.85 | 21.46 | 94 | 60123 | 25317 | 56206533 |
Crystal nephropathy | 49.11 | 21.46 | 22 | 60195 | 824 | 56231026 |
Musculoskeletal stiffness | 48.75 | 21.46 | 57 | 60160 | 155950 | 56075900 |
Protein total increased | 46.37 | 21.46 | 31 | 60186 | 2584 | 56229266 |
Fibromyalgia | 46.06 | 21.46 | 5 | 60212 | 59598 | 56172252 |
Hyponatraemia | 44.57 | 21.46 | 27 | 60190 | 102112 | 56129738 |
Hypokalaemia | 44.04 | 21.46 | 23 | 60194 | 94414 | 56137436 |
Vomiting | 42.75 | 21.46 | 335 | 59882 | 497893 | 55733957 |
Folliculitis | 41.51 | 21.46 | 5 | 60212 | 54974 | 56176876 |
Coma | 41.37 | 21.46 | 7 | 60210 | 59648 | 56172202 |
Monoclonal immunoglobulin present | 41.25 | 21.46 | 19 | 60198 | 760 | 56231090 |
COVID-19 pneumonia | 41.20 | 21.46 | 55 | 60162 | 11047 | 56220803 |
Malaise | 40.77 | 21.46 | 585 | 59632 | 367275 | 55864575 |
Anaphylactic reaction | 40.74 | 21.46 | 7 | 60210 | 58988 | 56172862 |
Aspartate aminotransferase increased | 40.20 | 21.46 | 19 | 60198 | 82583 | 56149267 |
Memory impairment | 39.25 | 21.46 | 190 | 60027 | 86367 | 56145483 |
Seasonal allergy | 38.27 | 21.46 | 67 | 60150 | 17041 | 56214809 |
Osteoarthritis | 38.27 | 21.46 | 19 | 60198 | 80277 | 56151573 |
Electrocardiogram QT prolonged | 36.57 | 21.46 | 7 | 60210 | 54581 | 56177269 |
Alanine aminotransferase increased | 36.54 | 21.46 | 28 | 60189 | 93634 | 56138216 |
Intentional product misuse | 35.81 | 21.46 | 6 | 60211 | 51498 | 56180352 |
Injection site swelling | 35.40 | 21.46 | 3 | 60214 | 43575 | 56188275 |
Dyspnoea | 35.14 | 21.46 | 855 | 59362 | 591722 | 55640128 |
Tachycardia | 34.91 | 21.46 | 37 | 60180 | 105839 | 56126011 |
Loss of personal independence in daily activities | 34.82 | 21.46 | 22 | 60195 | 81347 | 56150503 |
Respiratory tract infection | 34.80 | 21.46 | 101 | 60116 | 35970 | 56195880 |
Monoclonal immunoglobulin increased | 34.72 | 21.46 | 10 | 60207 | 98 | 56231752 |
Back disorder | 34.35 | 21.46 | 48 | 60169 | 10065 | 56221785 |
Tooth infection | 34.34 | 21.46 | 61 | 60156 | 15691 | 56216159 |
Blood potassium decreased | 34.20 | 21.46 | 105 | 60112 | 38567 | 56193283 |
Anxiety | 34.15 | 21.46 | 100 | 60117 | 193072 | 56038778 |
Seizure | 33.69 | 21.46 | 51 | 60166 | 125068 | 56106782 |
Liver injury | 33.67 | 21.46 | 3 | 60214 | 41845 | 56190005 |
Cerebrovascular accident | 33.52 | 21.46 | 201 | 60016 | 99069 | 56132781 |
Arthropathy | 33.05 | 21.46 | 107 | 60110 | 200168 | 56031682 |
Blood calcium increased | 32.75 | 21.46 | 42 | 60175 | 8112 | 56223738 |
Metabolic acidosis | 32.28 | 21.46 | 3 | 60214 | 40451 | 56191399 |
Agitation | 32.06 | 21.46 | 10 | 60207 | 56026 | 56175824 |
Pneumonia influenzal | 32.02 | 21.46 | 20 | 60197 | 1484 | 56230366 |
Inflammation | 31.94 | 21.46 | 17 | 60200 | 69054 | 56162796 |
Bone lesion | 31.89 | 21.46 | 34 | 60183 | 5396 | 56226454 |
Hypersensitivity | 31.52 | 21.46 | 154 | 60063 | 256254 | 55975596 |
Swelling face | 31.36 | 21.46 | 131 | 60086 | 55938 | 56175912 |
Swelling | 31.24 | 21.46 | 141 | 60076 | 239630 | 55992220 |
Dry skin | 30.31 | 21.46 | 115 | 60102 | 46994 | 56184856 |
Toxicity to various agents | 29.89 | 21.46 | 131 | 60086 | 224433 | 56007417 |
Cardio-respiratory arrest | 29.69 | 21.46 | 11 | 60206 | 55310 | 56176540 |
Inappropriate schedule of product administration | 28.79 | 21.46 | 28 | 60189 | 83359 | 56148491 |
Irritable bowel syndrome | 28.62 | 21.46 | 19 | 60198 | 68439 | 56163411 |
Suicidal ideation | 28.53 | 21.46 | 13 | 60204 | 57729 | 56174121 |
Pancytopenia | 28.28 | 21.46 | 177 | 60040 | 88538 | 56143312 |
General physical health deterioration | 27.92 | 21.46 | 91 | 60126 | 169919 | 56061931 |
Cystitis | 27.76 | 21.46 | 115 | 60102 | 48923 | 56182927 |
Dysphonia | 27.49 | 21.46 | 103 | 60114 | 41844 | 56190006 |
Depressed level of consciousness | 27.43 | 21.46 | 13 | 60204 | 56420 | 56175430 |
Feeling abnormal | 26.89 | 21.46 | 239 | 59978 | 133363 | 56098487 |
Vision blurred | 26.76 | 21.46 | 166 | 60051 | 82777 | 56149073 |
Amyloidosis | 26.60 | 21.46 | 16 | 60201 | 1109 | 56230741 |
SARS-CoV-2 test positive | 26.47 | 21.46 | 33 | 60184 | 6196 | 56225654 |
Hypoaesthesia | 25.89 | 21.46 | 248 | 59969 | 141243 | 56090607 |
Nervousness | 25.86 | 21.46 | 79 | 60138 | 28936 | 56202914 |
Injury | 25.86 | 21.46 | 16 | 60201 | 59835 | 56172015 |
Rash pruritic | 25.69 | 21.46 | 118 | 60099 | 52476 | 56179374 |
Coronavirus infection | 25.36 | 21.46 | 24 | 60193 | 3305 | 56228545 |
Spinal fracture | 25.35 | 21.46 | 55 | 60162 | 16369 | 56215481 |
Medication error | 25.23 | 21.46 | 7 | 60210 | 42328 | 56189522 |
Stress | 25.10 | 21.46 | 16 | 60201 | 58894 | 56172956 |
Oxygen saturation decreased | 24.56 | 21.46 | 29 | 60188 | 79038 | 56152812 |
Sedation | 24.36 | 21.46 | 4 | 60213 | 34850 | 56197000 |
Neoplasm progression | 23.95 | 21.46 | 3 | 60214 | 32013 | 56199837 |
Musculoskeletal pain | 23.91 | 21.46 | 31 | 60186 | 81121 | 56150729 |
Localised infection | 23.84 | 21.46 | 74 | 60143 | 27338 | 56204512 |
Upper respiratory tract infection | 23.84 | 21.46 | 144 | 60073 | 71144 | 56160706 |
Migraine | 23.73 | 21.46 | 35 | 60182 | 86762 | 56145088 |
Light chain analysis abnormal | 23.59 | 21.46 | 8 | 60209 | 139 | 56231711 |
Pseudomonas aeruginosa meningitis | 23.37 | 21.46 | 4 | 60213 | 0 | 56231850 |
International normalised ratio increased | 23.23 | 21.46 | 9 | 60208 | 44032 | 56187818 |
Liver function test abnormal | 23.01 | 21.46 | 10 | 60207 | 45661 | 56186189 |
Bradycardia | 22.92 | 21.46 | 23 | 60194 | 67481 | 56164369 |
Hypertension | 22.91 | 21.46 | 160 | 60057 | 244118 | 55987732 |
Hospitalisation | 22.78 | 21.46 | 28 | 60189 | 74972 | 56156878 |
Angioedema | 22.65 | 21.46 | 8 | 60209 | 41445 | 56190405 |
Fluid retention | 22.59 | 21.46 | 116 | 60101 | 53962 | 56177888 |
Blister | 22.58 | 21.46 | 52 | 60165 | 108835 | 56123015 |
Drug reaction with eosinophilia and systemic symptoms | 22.28 | 21.46 | 3 | 60214 | 30301 | 56201549 |
Osteolysis | 22.15 | 21.46 | 20 | 60197 | 2593 | 56229257 |
Balance disorder | 22.14 | 21.46 | 149 | 60068 | 76371 | 56155479 |
Peritonitis viral | 21.92 | 21.46 | 6 | 60211 | 48 | 56231802 |
Wheezing | 21.76 | 21.46 | 29 | 60188 | 74997 | 56156853 |
Tumour lysis syndrome | 21.71 | 21.46 | 34 | 60183 | 7889 | 56223961 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Plasma cell myeloma | 6507.36 | 18.88 | 2810 | 57948 | 53721 | 31582865 |
Death | 1910.82 | 18.88 | 2845 | 57913 | 357724 | 31278862 |
Pneumonia | 1513.64 | 18.88 | 2461 | 58297 | 332851 | 31303735 |
White blood cell count decreased | 1124.04 | 18.88 | 1089 | 59669 | 86309 | 31550277 |
Full blood count decreased | 1039.04 | 18.88 | 545 | 60213 | 15995 | 31620591 |
Fatigue | 885.31 | 18.88 | 1962 | 58796 | 333244 | 31303342 |
Laboratory test abnormal | 802.78 | 18.88 | 481 | 60277 | 18333 | 31618253 |
Neuropathy peripheral | 658.81 | 18.88 | 767 | 59991 | 74882 | 31561704 |
Adverse drug reaction | 542.13 | 18.88 | 422 | 60336 | 24779 | 31611807 |
Neutropenia | 522.65 | 18.88 | 951 | 59807 | 139413 | 31497173 |
Unevaluable event | 418.22 | 18.88 | 395 | 60363 | 30180 | 31606406 |
Thrombosis | 414.73 | 18.88 | 471 | 60287 | 44680 | 31591906 |
Influenza | 408.17 | 18.88 | 463 | 60295 | 43862 | 31592724 |
COVID-19 | 347.79 | 18.88 | 475 | 60283 | 54346 | 31582240 |
Drug interaction | 333.46 | 18.88 | 16 | 60742 | 208527 | 31428059 |
Plasma cell myeloma recurrent | 288.77 | 18.88 | 144 | 60614 | 3780 | 31632806 |
Peripheral swelling | 283.05 | 18.88 | 484 | 60274 | 67381 | 31569205 |
Constipation | 239 | 18.88 | 646 | 60112 | 123345 | 31513241 |
Nasopharyngitis | 207.83 | 18.88 | 407 | 60351 | 62838 | 31573748 |
Rash | 204.55 | 18.88 | 845 | 59913 | 200641 | 31435945 |
Neutrophil count decreased | 204.08 | 18.88 | 339 | 60419 | 46055 | 31590531 |
Platelet count decreased | 203.38 | 18.88 | 566 | 60192 | 109869 | 31526717 |
Condition aggravated | 192.53 | 18.88 | 40 | 60718 | 163969 | 31472617 |
Infection | 179.36 | 18.88 | 448 | 60310 | 81483 | 31555103 |
Cardiac disorder | 161.11 | 18.88 | 278 | 60480 | 38936 | 31597650 |
Plasmacytoma | 156.06 | 18.88 | 91 | 60667 | 3286 | 31633300 |
Muscle spasms | 152.04 | 18.88 | 376 | 60382 | 67942 | 31568644 |
Renal disorder | 137.98 | 18.88 | 197 | 60561 | 23448 | 31613138 |
Tooth disorder | 135.90 | 18.88 | 129 | 60629 | 9900 | 31626686 |
Back pain | 133.64 | 18.88 | 487 | 60271 | 108926 | 31527660 |
Overdose | 133.48 | 18.88 | 7 | 60751 | 84657 | 31551929 |
Illness | 130.82 | 18.88 | 122 | 60636 | 9155 | 31627431 |
Asthenia | 121.52 | 18.88 | 791 | 59967 | 223964 | 31412622 |
Product use in unapproved indication | 112.59 | 18.88 | 26 | 60732 | 99145 | 31537441 |
Product dose omission issue | 110.87 | 18.88 | 448 | 60310 | 105138 | 31531448 |
Plasma cell leukaemia | 94.75 | 18.88 | 43 | 60715 | 908 | 31635678 |
Localised infection | 93.21 | 18.88 | 130 | 60628 | 15135 | 31621451 |
Abdominal pain | 92.63 | 18.88 | 86 | 60672 | 145866 | 31490720 |
Deep vein thrombosis | 92.26 | 18.88 | 291 | 60467 | 60445 | 31576141 |
Hyponatraemia | 90.72 | 18.88 | 16 | 60742 | 73783 | 31562803 |
Light chain analysis increased | 90.08 | 18.88 | 45 | 60713 | 1185 | 31635401 |
Immune system disorder | 89.33 | 18.88 | 72 | 60686 | 4436 | 31632150 |
Rhabdomyolysis | 86.97 | 18.88 | 10 | 60748 | 63571 | 31573015 |
Toxicity to various agents | 85.46 | 18.88 | 135 | 60623 | 181352 | 31455234 |
Full blood count abnormal | 83.55 | 18.88 | 128 | 60630 | 16219 | 31620367 |
Aspartate aminotransferase increased | 83.01 | 18.88 | 11 | 60747 | 62708 | 31573878 |
Drug intolerance | 82.44 | 18.88 | 253 | 60505 | 51780 | 31584806 |
Vomiting | 81.67 | 18.88 | 194 | 60564 | 223779 | 31412807 |
Acute kidney injury | 80.15 | 18.88 | 272 | 60486 | 279442 | 31357144 |
Rheumatoid arthritis | 78.45 | 18.88 | 3 | 60755 | 47806 | 31588780 |
Sepsis | 74.88 | 18.88 | 523 | 60235 | 151406 | 31485180 |
Alanine aminotransferase increased | 71.19 | 18.88 | 27 | 60731 | 74629 | 31561957 |
Monoclonal immunoglobulin present | 70.85 | 18.88 | 35 | 60723 | 899 | 31635687 |
Full blood count increased | 69.78 | 18.88 | 33 | 60725 | 768 | 31635818 |
Bronchitis | 68.69 | 18.88 | 196 | 60562 | 38521 | 31598065 |
Hypoglycaemia | 67.26 | 18.88 | 9 | 60749 | 50937 | 31585649 |
Psoriasis | 64.77 | 18.88 | 7 | 60751 | 46712 | 31589874 |
Blood test abnormal | 63.06 | 18.88 | 68 | 60690 | 6073 | 31630513 |
Agitation | 61.85 | 18.88 | 14 | 60744 | 54155 | 31582431 |
Hyperkalaemia | 61.80 | 18.88 | 23 | 60735 | 64328 | 31572258 |
Bone pain | 59.22 | 18.88 | 121 | 60637 | 19230 | 31617356 |
Sinusitis | 57.70 | 18.88 | 178 | 60580 | 36518 | 31600068 |
Cytopenia | 57.37 | 18.88 | 87 | 60671 | 10923 | 31625663 |
Atrial fibrillation | 57.37 | 18.88 | 394 | 60364 | 113389 | 31523197 |
Ascites | 57.22 | 18.88 | 6 | 60752 | 41007 | 31595579 |
Red blood cell count decreased | 53.80 | 18.88 | 142 | 60616 | 26665 | 31609921 |
Suicide attempt | 53.14 | 18.88 | 5 | 60753 | 37243 | 31599343 |
Fluid retention | 52.46 | 18.88 | 134 | 60624 | 24668 | 31611918 |
Electrocardiogram QT prolonged | 51.87 | 18.88 | 6 | 60752 | 37981 | 31598605 |
Wrong technique in product usage process | 51.77 | 18.88 | 3 | 60755 | 33340 | 31603246 |
Back disorder | 51.54 | 18.88 | 61 | 60697 | 6032 | 31630554 |
Off label use | 51.36 | 18.88 | 423 | 60335 | 346851 | 31289735 |
Aggression | 50.65 | 18.88 | 6 | 60752 | 37285 | 31599301 |
Cellulitis enterococcal | 48.79 | 18.88 | 15 | 60743 | 98 | 31636488 |
Cataract | 48.68 | 18.88 | 127 | 60631 | 23680 | 31612906 |
Anxiety | 48.44 | 18.88 | 62 | 60696 | 90971 | 31545615 |
International normalised ratio increased | 47.20 | 18.88 | 14 | 60744 | 45209 | 31591377 |
Adverse event | 47.08 | 18.88 | 101 | 60657 | 16604 | 31619982 |
Hypotension | 47.02 | 18.88 | 217 | 60541 | 204401 | 31432185 |
Hypokalaemia | 46.85 | 18.88 | 22 | 60736 | 53552 | 31583034 |
Injection site pain | 46.00 | 18.88 | 6 | 60752 | 34628 | 31601958 |
Interstitial lung disease | 45.40 | 18.88 | 31 | 60727 | 61372 | 31575214 |
SARS-CoV-2 test positive | 45.29 | 18.88 | 49 | 60709 | 4392 | 31632194 |
Arthropathy | 44.84 | 18.88 | 124 | 60634 | 23927 | 31612659 |
Coma | 44.32 | 18.88 | 12 | 60746 | 41138 | 31595448 |
Inappropriate schedule of product administration | 44.24 | 18.88 | 21 | 60737 | 50802 | 31585784 |
Pulmonary thrombosis | 44.08 | 18.88 | 60 | 60698 | 6825 | 31629761 |
Dyspnoea | 43.77 | 18.88 | 911 | 59847 | 342568 | 31294018 |
Tachycardia | 43.63 | 18.88 | 49 | 60709 | 76158 | 31560428 |
Rib fracture | 42.81 | 18.88 | 85 | 60673 | 13231 | 31623355 |
Seizure | 42.50 | 18.88 | 79 | 60679 | 99689 | 31536897 |
General physical health deterioration | 42.26 | 18.88 | 97 | 60661 | 113338 | 31523248 |
White blood cell count abnormal | 41.34 | 18.88 | 39 | 60719 | 2968 | 31633618 |
Pancreatitis | 41.32 | 18.88 | 9 | 60749 | 35762 | 31600824 |
Haematuria | 40.52 | 18.88 | 19 | 60739 | 46295 | 31590291 |
Depressed level of consciousness | 40.19 | 18.88 | 12 | 60746 | 38589 | 31597997 |
Incorrect dose administered | 39.31 | 18.88 | 10 | 60748 | 35742 | 31600844 |
Bradycardia | 39.22 | 18.88 | 45 | 60713 | 69282 | 31567304 |
Dysarthria | 39.20 | 18.88 | 7 | 60751 | 32010 | 31604576 |
Drug hypersensitivity | 39.08 | 18.88 | 49 | 60709 | 72550 | 31564036 |
Blood calcium increased | 38.25 | 18.88 | 39 | 60719 | 3263 | 31633323 |
Melaena | 38.16 | 18.88 | 8 | 60750 | 32646 | 31603940 |
Drug reaction with eosinophilia and systemic symptoms | 38.00 | 18.88 | 6 | 60752 | 30012 | 31606574 |
Upper limb fracture | 37.96 | 18.88 | 44 | 60714 | 4255 | 31632331 |
Headache | 37.46 | 18.88 | 203 | 60555 | 183449 | 31453137 |
COVID-19 pneumonia | 37.38 | 18.88 | 78 | 60680 | 12577 | 31624009 |
Gastrointestinal haemorrhage | 37.29 | 18.88 | 63 | 60695 | 82486 | 31554100 |
Cholestasis | 36.76 | 18.88 | 3 | 60755 | 25072 | 31611514 |
Squamous cell carcinoma of skin | 36.45 | 18.88 | 68 | 60690 | 10106 | 31626480 |
Hip fracture | 36.37 | 18.88 | 71 | 60687 | 10915 | 31625671 |
Jaundice | 36.27 | 18.88 | 7 | 60751 | 30280 | 31606306 |
Mucosal inflammation | 35.31 | 18.88 | 11 | 60747 | 34416 | 31602170 |
Hypoaesthesia | 35.02 | 18.88 | 205 | 60553 | 55817 | 31580769 |
Cardiac arrest | 34.93 | 18.88 | 74 | 60684 | 88988 | 31547598 |
Oxygen saturation decreased | 34.73 | 18.88 | 26 | 60732 | 49089 | 31587497 |
Balance disorder | 34.69 | 18.88 | 153 | 60605 | 37269 | 31599317 |
Coronary artery disease | 34.42 | 18.88 | 23 | 60735 | 46064 | 31590522 |
Respiratory tract infection | 34.19 | 18.88 | 92 | 60666 | 17469 | 31619117 |
Angioedema | 34.02 | 18.88 | 11 | 60747 | 33607 | 31602979 |
JC virus infection | 33.60 | 18.88 | 29 | 60729 | 1965 | 31634621 |
Protein total increased | 33.38 | 18.88 | 30 | 60728 | 2145 | 31634441 |
Body height decreased | 32.83 | 18.88 | 37 | 60721 | 3470 | 31633116 |
Drug ineffective | 32.66 | 18.88 | 548 | 60210 | 395025 | 31241561 |
Dizziness | 32.46 | 18.88 | 549 | 60209 | 198598 | 31437988 |
Bone lesion | 32.24 | 18.88 | 33 | 60725 | 2774 | 31633812 |
Gamma-glutamyltransferase increased | 32.14 | 18.88 | 7 | 60751 | 27818 | 31608768 |
White blood cell disorder | 31.93 | 18.88 | 25 | 60733 | 1476 | 31635110 |
Psychotic disorder | 31.78 | 18.88 | 3 | 60755 | 22290 | 31614296 |
Hepatic function abnormal | 31.57 | 18.88 | 20 | 60738 | 41202 | 31595384 |
Stress | 31.53 | 18.88 | 5 | 60753 | 24936 | 31611650 |
Lower respiratory tract infection | 31.32 | 18.88 | 122 | 60636 | 28115 | 31608471 |
Progressive multifocal leukoencephalopathy | 31.06 | 18.88 | 60 | 60698 | 9153 | 31627433 |
Acute myocardial infarction | 30.96 | 18.88 | 31 | 60727 | 50792 | 31585794 |
Metabolic acidosis | 30.58 | 18.88 | 19 | 60739 | 39558 | 31597028 |
Haematemesis | 30.57 | 18.88 | 6 | 60752 | 25647 | 31610939 |
Gastric disorder | 30.55 | 18.88 | 68 | 60690 | 11460 | 31625126 |
Multiple allergies | 30.49 | 18.88 | 30 | 60728 | 2405 | 31634181 |
Tooth infection | 30.36 | 18.88 | 47 | 60711 | 6007 | 31630579 |
Feeling abnormal | 30.24 | 18.88 | 200 | 60558 | 56802 | 31579784 |
Blood urea increased | 30.24 | 18.88 | 9 | 60749 | 29003 | 31607583 |
Hypercalcaemia | 29.97 | 18.88 | 76 | 60682 | 13924 | 31622662 |
Agranulocytosis | 29.91 | 18.88 | 3 | 60755 | 21244 | 31615342 |
Cardio-respiratory arrest | 29.88 | 18.88 | 33 | 60725 | 51693 | 31584893 |
Blood bilirubin increased | 29.84 | 18.88 | 15 | 60743 | 35121 | 31601465 |
Pneumonia respiratory syncytial viral | 29.72 | 18.88 | 19 | 60739 | 811 | 31635775 |
Lactic acidosis | 29.68 | 18.88 | 12 | 60746 | 31925 | 31604661 |
Epilepsy | 29.55 | 18.88 | 3 | 60755 | 21038 | 31615548 |
Malaise | 29.47 | 18.88 | 470 | 60288 | 168041 | 31468545 |
Fall | 29.23 | 18.88 | 510 | 60248 | 185579 | 31451007 |
Encephalopathy | 28.91 | 18.88 | 13 | 60745 | 32461 | 31604125 |
Blood immunoglobulin M increased | 28.66 | 18.88 | 12 | 60746 | 207 | 31636379 |
Respiration abnormal | 28.54 | 18.88 | 31 | 60727 | 2791 | 31633795 |
Parainfluenzae virus infection | 28.51 | 18.88 | 29 | 60729 | 2420 | 31634166 |
Drug-induced liver injury | 28.40 | 18.88 | 6 | 60752 | 24357 | 31612229 |
Musculoskeletal disorder | 27.98 | 18.88 | 44 | 60714 | 5700 | 31630886 |
Anaphylactic reaction | 27.64 | 18.88 | 11 | 60747 | 29542 | 31607044 |
Spinal fracture | 27.17 | 18.88 | 48 | 60710 | 6840 | 31629746 |
Product prescribing error | 27.07 | 18.88 | 3 | 60755 | 19639 | 31616947 |
Respiratory syncytial virus infection | 27.00 | 18.88 | 35 | 60723 | 3796 | 31632790 |
Toxic epidermal necrolysis | 26.86 | 18.88 | 3 | 60755 | 19521 | 31617065 |
Transaminases increased | 26.39 | 18.88 | 7 | 60751 | 24334 | 31612252 |
Neutropenic sepsis | 26.29 | 18.88 | 67 | 60691 | 12312 | 31624274 |
Hepatotoxicity | 26.16 | 18.88 | 3 | 60755 | 19123 | 31617463 |
Blood alkaline phosphatase increased | 25.89 | 18.88 | 12 | 60746 | 29441 | 31607145 |
Blood lactate dehydrogenase increased | 25.89 | 18.88 | 4 | 60754 | 20335 | 31616251 |
Respiratory arrest | 25.85 | 18.88 | 9 | 60749 | 26248 | 31610338 |
Clostridium difficile infection | 25.48 | 18.88 | 82 | 60676 | 17197 | 31619389 |
White blood cell count increased | 24.67 | 18.88 | 23 | 60735 | 38977 | 31597609 |
Blood creatinine increased | 24.47 | 18.88 | 88 | 60670 | 88990 | 31547596 |
Blood immunoglobulin A increased | 24.37 | 18.88 | 12 | 60746 | 306 | 31636280 |
Therapeutic product effect incomplete | 24.02 | 18.88 | 29 | 60729 | 43667 | 31592919 |
C-reactive protein increased | 23.98 | 18.88 | 35 | 60723 | 48615 | 31587971 |
Lower limb fracture | 23.91 | 18.88 | 33 | 60725 | 3802 | 31632784 |
Medication error | 23.85 | 18.88 | 7 | 60751 | 22765 | 31613821 |
Protein total abnormal | 23.74 | 18.88 | 12 | 60746 | 324 | 31636262 |
Blood pressure abnormal | 23.64 | 18.88 | 47 | 60711 | 7322 | 31629264 |
Ventricular tachycardia | 23.55 | 18.88 | 8 | 60750 | 23693 | 31612893 |
Upper respiratory tract infection | 23.37 | 18.88 | 115 | 60643 | 29307 | 31607279 |
Cardiogenic shock | 23.26 | 18.88 | 7 | 60751 | 22401 | 31614185 |
Vertebral lesion | 23.19 | 18.88 | 10 | 60748 | 186 | 31636400 |
Generalised tonic-clonic seizure | 23.05 | 18.88 | 5 | 60753 | 19926 | 31616660 |
Leukocytosis | 22.79 | 18.88 | 7 | 60751 | 22107 | 31614479 |
Pneumonia influenzal | 22.75 | 18.88 | 20 | 60738 | 1389 | 31635197 |
Circulatory collapse | 22.73 | 18.88 | 5 | 60753 | 19739 | 31616847 |
Cerebral toxoplasmosis | 22.73 | 18.88 | 21 | 60737 | 1556 | 31635030 |
Pyrexia | 22.58 | 18.88 | 751 | 60007 | 303089 | 31333497 |
Sinus disorder | 22.46 | 18.88 | 42 | 60716 | 6253 | 31630333 |
Product use issue | 22.38 | 18.88 | 47 | 60711 | 56712 | 31579874 |
Thrombocytopenia | 22.31 | 18.88 | 391 | 60367 | 142356 | 31494230 |
Blood pressure systolic increased | 22.28 | 18.88 | 5 | 60753 | 19465 | 31617121 |
Seasonal allergy | 22.12 | 18.88 | 39 | 60719 | 5549 | 31631037 |
Abnormal behaviour | 22.07 | 18.88 | 9 | 60749 | 23819 | 31612767 |
Arthralgia | 22.02 | 18.88 | 185 | 60573 | 151239 | 31485347 |
Pleural effusion | 21.94 | 18.88 | 72 | 60686 | 74848 | 31561738 |
Shock | 21.89 | 18.88 | 8 | 60750 | 22637 | 31613949 |
Tremor | 21.69 | 18.88 | 233 | 60525 | 76187 | 31560399 |
Haemoptysis | 21.54 | 18.88 | 18 | 60740 | 32171 | 31604415 |
Drug resistance | 21.49 | 18.88 | 9 | 60749 | 23444 | 31613142 |
Nausea | 21.48 | 18.88 | 439 | 60319 | 307508 | 31329078 |
Sedation | 21.44 | 18.88 | 5 | 60753 | 18960 | 31617626 |
Eosinophilia | 21.18 | 18.88 | 9 | 60749 | 23244 | 31613342 |
Product quality issue | 20.89 | 18.88 | 3 | 60755 | 16108 | 31620478 |
Dyskinesia | 20.88 | 18.88 | 7 | 60751 | 20903 | 31615683 |
Hospitalisation | 20.70 | 18.88 | 40 | 60718 | 49767 | 31586819 |
Hepatic enzyme increased | 20.64 | 18.88 | 23 | 60735 | 35885 | 31600701 |
Hallucination, visual | 20.35 | 18.88 | 3 | 60755 | 15791 | 31620795 |
Viral infection | 20.33 | 18.88 | 71 | 60687 | 15522 | 31621064 |
Hypertension | 20.24 | 18.88 | 153 | 60605 | 127947 | 31508639 |
Dysphagia | 20.13 | 18.88 | 51 | 60707 | 57625 | 31578961 |
Clonal haematopoiesis | 19.90 | 18.88 | 7 | 60751 | 73 | 31636513 |
Respiratory distress | 19.83 | 18.88 | 21 | 60737 | 33532 | 31603054 |
Restlessness | 19.80 | 18.88 | 10 | 60748 | 23351 | 31613235 |
Myocardial ischaemia | 19.64 | 18.88 | 4 | 60754 | 16663 | 31619923 |
Upper gastrointestinal haemorrhage | 19.53 | 18.88 | 10 | 60748 | 23173 | 31613413 |
Swelling face | 19.47 | 18.88 | 87 | 60671 | 21303 | 31615283 |
Hiccups | 19.45 | 18.88 | 50 | 60708 | 9237 | 31627349 |
Monoclonal immunoglobulin increased | 19.33 | 18.88 | 7 | 60751 | 80 | 31636506 |
Hypoacusis | 19.30 | 18.88 | 68 | 60690 | 14931 | 31621655 |
Ageusia | 19.30 | 18.88 | 50 | 60708 | 9281 | 31627305 |
Wound infection | 19.23 | 18.88 | 40 | 60718 | 6435 | 31630151 |
Malignant neoplasm progression | 19.17 | 18.88 | 82 | 60676 | 78916 | 31557670 |
Unresponsive to stimuli | 19.10 | 18.88 | 13 | 60745 | 25787 | 31610799 |
Haematochezia | 19.08 | 18.88 | 30 | 60728 | 40434 | 31596152 |
Spinal disorder | 19.05 | 18.88 | 30 | 60728 | 3890 | 31632696 |
Coronavirus infection | 19.04 | 18.88 | 29 | 60729 | 3654 | 31632932 |
Rectal haemorrhage | 19.01 | 18.88 | 25 | 60733 | 36279 | 31600307 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Plasma cell myeloma | 10336.74 | 18.45 | 3566 | 69685 | 69635 | 70785558 |
Death | 3138.76 | 18.45 | 3194 | 70057 | 506867 | 70348326 |
Pneumonia | 2388.11 | 18.45 | 2989 | 70262 | 593243 | 70261950 |
White blood cell count decreased | 1451.89 | 18.45 | 1283 | 71968 | 168858 | 70686335 |
Neutropenia | 1336.49 | 18.45 | 1479 | 71772 | 255677 | 70599516 |
Full blood count decreased | 1296.41 | 18.45 | 586 | 72665 | 23332 | 70831861 |
Neuropathy peripheral | 775.89 | 18.45 | 797 | 72454 | 126099 | 70729094 |
Fatigue | 565.25 | 18.45 | 1996 | 71255 | 822323 | 70032870 |
Neutrophil count decreased | 562.05 | 18.45 | 553 | 72698 | 83003 | 70772190 |
Thrombosis | 540.85 | 18.45 | 517 | 72734 | 74888 | 70780305 |
Platelet count decreased | 512.65 | 18.45 | 766 | 72485 | 177456 | 70677737 |
Laboratory test abnormal | 472.77 | 18.45 | 308 | 72943 | 25515 | 70829678 |
COVID-19 | 360.25 | 18.45 | 493 | 72758 | 105264 | 70749929 |
Plasma cell myeloma recurrent | 353.14 | 18.45 | 142 | 73109 | 4204 | 70850989 |
Unevaluable event | 339.53 | 18.45 | 339 | 72912 | 51724 | 70803469 |
Plasmacytoma | 324.37 | 18.45 | 131 | 73120 | 3923 | 70851270 |
Influenza | 314.17 | 18.45 | 480 | 72771 | 113220 | 70741973 |
Drug interaction | 303.71 | 18.45 | 24 | 73227 | 381417 | 70473776 |
Rheumatoid arthritis | 280.68 | 18.45 | 4 | 73247 | 291801 | 70563392 |
Condition aggravated | 264.88 | 18.45 | 59 | 73192 | 427576 | 70427617 |
Constipation | 230.95 | 18.45 | 677 | 72574 | 251761 | 70603432 |
Sepsis | 221.93 | 18.45 | 654 | 72597 | 243891 | 70611302 |
Thrombocytopenia | 221.33 | 18.45 | 644 | 72607 | 238466 | 70616727 |
Deep vein thrombosis | 200.11 | 18.45 | 388 | 72863 | 110654 | 70744539 |
Plasma cell leukaemia | 169.00 | 18.45 | 66 | 73185 | 1805 | 70853388 |
Human chorionic gonadotropin increased | 167.69 | 18.45 | 56 | 73195 | 962 | 70854231 |
Anaemia | 166.16 | 18.45 | 839 | 72412 | 402584 | 70452609 |
Rash | 164.98 | 18.45 | 994 | 72257 | 509568 | 70345625 |
Muscle spasms | 150.22 | 18.45 | 423 | 72828 | 153623 | 70701570 |
Cytopenia | 149.79 | 18.45 | 132 | 73119 | 17191 | 70838002 |
Atrial fibrillation | 145.65 | 18.45 | 470 | 72781 | 183878 | 70671315 |
Drug hypersensitivity | 143.81 | 18.45 | 46 | 73205 | 262413 | 70592780 |
Light chain analysis increased | 140.08 | 18.45 | 54 | 73197 | 1425 | 70853768 |
Product dose omission issue | 136.73 | 18.45 | 514 | 72737 | 216954 | 70638239 |
Overdose | 126.10 | 18.45 | 14 | 73237 | 169731 | 70685462 |
Infection | 125.76 | 18.45 | 490 | 72761 | 210295 | 70644898 |
Drug ineffective | 123.08 | 18.45 | 527 | 72724 | 939225 | 69915968 |
Adverse drug reaction | 120.94 | 18.45 | 206 | 73045 | 53138 | 70802055 |
Arthralgia | 115.68 | 18.45 | 215 | 73036 | 503175 | 70352018 |
Abdominal pain | 113.05 | 18.45 | 112 | 73139 | 342015 | 70513178 |
Asthenia | 112.01 | 18.45 | 832 | 72419 | 456834 | 70398359 |
Product use in unapproved indication | 109.04 | 18.45 | 39 | 73212 | 207439 | 70647754 |
Bronchitis | 106.56 | 18.45 | 314 | 72937 | 116929 | 70738264 |
Cardiac disorder | 100.18 | 18.45 | 202 | 73049 | 59213 | 70795980 |
Headache | 99.51 | 18.45 | 290 | 72961 | 580115 | 70275078 |
Peripheral swelling | 93.66 | 18.45 | 487 | 72764 | 236076 | 70619117 |
Red blood cell count decreased | 92.34 | 18.45 | 181 | 73070 | 51980 | 70803213 |
Hypercalcaemia | 91.79 | 18.45 | 143 | 73108 | 34242 | 70820951 |
Injection site pain | 89.14 | 18.45 | 9 | 73242 | 117610 | 70737583 |
Renal disorder | 89.09 | 18.45 | 149 | 73102 | 37860 | 70817333 |
Bone pain | 84.74 | 18.45 | 172 | 73079 | 50650 | 70804543 |
Febrile neutropenia | 83.90 | 18.45 | 425 | 72826 | 203893 | 70651300 |
Pulmonary thrombosis | 78.63 | 18.45 | 76 | 73175 | 11132 | 70844061 |
Urinary tract infection | 77.91 | 18.45 | 481 | 72770 | 248288 | 70606905 |
COVID-19 pneumonia | 77.08 | 18.45 | 104 | 73147 | 21865 | 70833328 |
Psoriasis | 75.99 | 18.45 | 7 | 73244 | 98426 | 70756767 |
Neutropenic sepsis | 75.87 | 18.45 | 110 | 73141 | 24720 | 70830473 |
Therapeutic product effect decreased | 74.92 | 18.45 | 27 | 73224 | 142991 | 70712202 |
Hip fracture | 74.68 | 18.45 | 117 | 73134 | 28146 | 70827047 |
Pericarditis | 71.19 | 18.45 | 4 | 73247 | 84701 | 70770492 |
Vomiting | 71.14 | 18.45 | 343 | 72908 | 592768 | 70262425 |
Treatment failure | 69.32 | 18.45 | 31 | 73220 | 144111 | 70711082 |
Pancytopenia | 68.94 | 18.45 | 324 | 72927 | 150783 | 70704410 |
Respiratory tract infection | 68.92 | 18.45 | 142 | 73109 | 42256 | 70812937 |
Hyponatraemia | 68.67 | 18.45 | 40 | 73211 | 160047 | 70695146 |
Pyrexia | 68.40 | 18.45 | 940 | 72311 | 606012 | 70249181 |
Rhabdomyolysis | 68.38 | 18.45 | 9 | 73242 | 95751 | 70759442 |
Fall | 66.57 | 18.45 | 726 | 72525 | 443370 | 70411823 |
Squamous cell carcinoma of skin | 65.40 | 18.45 | 73 | 73178 | 12639 | 70842554 |
Anxiety | 64.07 | 18.45 | 80 | 73171 | 220250 | 70634943 |
Musculoskeletal stiffness | 63.27 | 18.45 | 37 | 73214 | 147723 | 70707470 |
Injection site erythema | 62.68 | 18.45 | 3 | 73248 | 72921 | 70782272 |
Hepatic enzyme increased | 62.16 | 18.45 | 43 | 73208 | 156947 | 70698246 |
Haemoglobin decreased | 61.90 | 18.45 | 393 | 72858 | 204766 | 70650427 |
Nasopharyngitis | 61.18 | 18.45 | 416 | 72835 | 221790 | 70633403 |
Suicide attempt | 60.46 | 18.45 | 6 | 73245 | 79504 | 70775689 |
Monoclonal immunoglobulin present | 57.89 | 18.45 | 25 | 73226 | 888 | 70854305 |
Stress | 57.77 | 18.45 | 3 | 73248 | 67963 | 70787230 |
Agitation | 57.43 | 18.45 | 13 | 73238 | 93362 | 70761831 |
Aspartate aminotransferase increased | 56.96 | 18.45 | 30 | 73221 | 126948 | 70728245 |
Discomfort | 56.77 | 18.45 | 19 | 73232 | 105417 | 70749776 |
Intentional product misuse | 55.60 | 18.45 | 8 | 73243 | 79587 | 70775606 |
Back pain | 55.23 | 18.45 | 473 | 72778 | 270679 | 70584514 |
Tremor | 55.18 | 18.45 | 311 | 72940 | 155313 | 70699880 |
Coma | 54.11 | 18.45 | 14 | 73237 | 91830 | 70763363 |
Infusion related reaction | 54.07 | 18.45 | 75 | 73176 | 197459 | 70657734 |
Pain | 53.59 | 18.45 | 405 | 72846 | 628411 | 70226782 |
Glossodynia | 53.27 | 18.45 | 12 | 73239 | 86475 | 70768718 |
Hypertension | 52.74 | 18.45 | 145 | 73106 | 295888 | 70559305 |
Pulmonary embolism | 52.32 | 18.45 | 307 | 72944 | 155560 | 70699633 |
Blood calcium increased | 52.13 | 18.45 | 55 | 73196 | 8938 | 70846255 |
Respiratory syncytial virus infection | 52.00 | 18.45 | 51 | 73200 | 7604 | 70847589 |
Diarrhoea | 51.38 | 18.45 | 1112 | 72139 | 782229 | 70072964 |
Leukopenia | 51.18 | 18.45 | 232 | 73019 | 106328 | 70748865 |
Electrocardiogram QT prolonged | 50.62 | 18.45 | 12 | 73239 | 83505 | 70771688 |
Therapeutic product effect incomplete | 49.94 | 18.45 | 31 | 73220 | 119851 | 70735342 |
Hypokalaemia | 49.24 | 18.45 | 38 | 73213 | 131150 | 70724043 |
Renal failure | 48.52 | 18.45 | 348 | 72903 | 188722 | 70666471 |
Toxicity to various agents | 46.90 | 18.45 | 219 | 73032 | 381953 | 70473240 |
Cerebrovascular accident | 46.49 | 18.45 | 280 | 72971 | 143190 | 70712003 |
Wound | 46.27 | 18.45 | 22 | 73229 | 98710 | 70756483 |
Progressive multifocal leukoencephalopathy | 45.92 | 18.45 | 76 | 73175 | 19138 | 70836055 |
Adverse event | 45.40 | 18.45 | 133 | 73118 | 49328 | 70805865 |
Rib fracture | 44.88 | 18.45 | 88 | 73163 | 25268 | 70829925 |
Product use issue | 44.71 | 18.45 | 73 | 73178 | 179864 | 70675329 |
Tooth disorder | 43.49 | 18.45 | 84 | 73167 | 23854 | 70831339 |
Immune system disorder | 43.23 | 18.45 | 52 | 73199 | 9749 | 70845444 |
Hypoglycaemia | 42.75 | 18.45 | 22 | 73229 | 94342 | 70760851 |
Mobility decreased | 42.40 | 18.45 | 27 | 73224 | 102972 | 70752221 |
Alanine aminotransferase increased | 41.35 | 18.45 | 55 | 73196 | 147425 | 70707768 |
Dyspnoea | 41.21 | 18.45 | 1063 | 72188 | 768997 | 70086196 |
Crystal nephropathy | 41.03 | 18.45 | 22 | 73229 | 1268 | 70853925 |
Impaired healing | 40.74 | 18.45 | 13 | 73238 | 74361 | 70780832 |
Inflammation | 39.27 | 18.45 | 16 | 73235 | 78649 | 70776544 |
Osteoarthritis | 38.81 | 18.45 | 14 | 73237 | 74133 | 70781060 |
Aggression | 38.61 | 18.45 | 3 | 73248 | 48443 | 70806750 |
Pneumonia influenzal | 37.92 | 18.45 | 27 | 73224 | 2583 | 70852610 |
Oxygen saturation decreased | 37.38 | 18.45 | 39 | 73212 | 116390 | 70738803 |
Cellulitis enterococcal | 36.98 | 18.45 | 9 | 73242 | 44 | 70855149 |
Full blood count abnormal | 36.93 | 18.45 | 97 | 73154 | 33781 | 70821412 |
Dizziness | 36.70 | 18.45 | 678 | 72573 | 463463 | 70391730 |
Suicidal ideation | 36.67 | 18.45 | 13 | 73238 | 69583 | 70785610 |
Blood test abnormal | 36.62 | 18.45 | 59 | 73192 | 14531 | 70840662 |
SARS-CoV-2 test positive | 36.49 | 18.45 | 45 | 73206 | 8656 | 70846537 |
Anaphylactic reaction | 36.23 | 18.45 | 16 | 73235 | 74958 | 70780235 |
Lymphocyte count decreased | 36.13 | 18.45 | 113 | 73138 | 43426 | 70811767 |
Peripheral sensory neuropathy | 36.05 | 18.45 | 53 | 73198 | 12057 | 70843136 |
Full blood count increased | 36.05 | 18.45 | 15 | 73236 | 485 | 70854708 |
Hypotension | 35.54 | 18.45 | 258 | 72993 | 404123 | 70451070 |
White blood cell count abnormal | 35.25 | 18.45 | 35 | 73216 | 5295 | 70849898 |
Weight decreased | 35.14 | 18.45 | 183 | 73068 | 310305 | 70544888 |
Pneumonia pneumococcal | 34.91 | 18.45 | 29 | 73222 | 3485 | 70851708 |
International normalised ratio increased | 34.85 | 18.45 | 20 | 73231 | 80706 | 70774487 |
JC virus infection | 34.64 | 18.45 | 29 | 73222 | 3522 | 70851671 |
Depressed level of consciousness | 34.52 | 18.45 | 24 | 73227 | 87407 | 70767786 |
Lactic acidosis | 34.51 | 18.45 | 12 | 73239 | 65012 | 70790181 |
Type 2 diabetes mellitus | 34.38 | 18.45 | 3 | 73248 | 44077 | 70811116 |
Amyloidosis | 34.17 | 18.45 | 26 | 73225 | 2753 | 70852440 |
Angioedema | 34.15 | 18.45 | 13 | 73238 | 66597 | 70788596 |
Drug-induced liver injury | 34.13 | 18.45 | 8 | 73243 | 56105 | 70799088 |
Back disorder | 34.03 | 18.45 | 48 | 73203 | 10516 | 70844677 |
Upper respiratory tract infection | 33.97 | 18.45 | 167 | 73084 | 79107 | 70776086 |
Drug reaction with eosinophilia and systemic symptoms | 33.87 | 18.45 | 9 | 73242 | 58004 | 70797189 |
Haematemesis | 33.86 | 18.45 | 5 | 73246 | 48792 | 70806401 |
Depression | 33.54 | 18.45 | 100 | 73151 | 198874 | 70656319 |
Inappropriate schedule of product administration | 33.44 | 18.45 | 37 | 73214 | 107518 | 70747675 |
Medication error | 32.90 | 18.45 | 9 | 73242 | 56903 | 70798290 |
Incorrect dose administered | 32.61 | 18.45 | 14 | 73237 | 66705 | 70788488 |
Melaena | 32.42 | 18.45 | 9 | 73242 | 56346 | 70798847 |
Sedation | 31.94 | 18.45 | 5 | 73246 | 46726 | 70808467 |
Pathological fracture | 31.55 | 18.45 | 44 | 73207 | 9539 | 70845654 |
Dyskinesia | 31.48 | 18.45 | 3 | 73248 | 41071 | 70814122 |
Blood pressure systolic increased | 31.38 | 18.45 | 10 | 73241 | 57249 | 70797944 |
Loss of personal independence in daily activities | 31.34 | 18.45 | 25 | 73226 | 84885 | 70770308 |
Blood pressure fluctuation | 31.13 | 18.45 | 11 | 73240 | 59001 | 70796192 |
Parainfluenzae virus infection | 31.11 | 18.45 | 32 | 73219 | 5048 | 70850145 |
Bone lesion | 31.10 | 18.45 | 33 | 73218 | 5397 | 70849796 |
Tumour lysis syndrome | 30.63 | 18.45 | 68 | 73183 | 21292 | 70833901 |
Cataract | 30.42 | 18.45 | 126 | 73125 | 55519 | 70799674 |
Pneumonia respiratory syncytial viral | 30.40 | 18.45 | 19 | 73232 | 1462 | 70853731 |
Rash pruritic | 30.12 | 18.45 | 137 | 73114 | 62854 | 70792339 |
Toxic epidermal necrolysis | 30.03 | 18.45 | 3 | 73248 | 39554 | 70815639 |
Tachycardia | 29.46 | 18.45 | 76 | 73175 | 158470 | 70696723 |
Weight increased | 29.03 | 18.45 | 140 | 73111 | 242191 | 70613002 |
Ascites | 28.78 | 18.45 | 17 | 73234 | 67530 | 70787663 |
Hepatitis | 28.71 | 18.45 | 8 | 73243 | 49972 | 70805221 |
Injury | 28.40 | 18.45 | 16 | 73235 | 65229 | 70789964 |
Folliculitis | 28.11 | 18.45 | 5 | 73246 | 42565 | 70812628 |
Blood immunoglobulin M increased | 28.02 | 18.45 | 13 | 73238 | 548 | 70854645 |
Blood cholesterol increased | 27.89 | 18.45 | 16 | 73235 | 64588 | 70790605 |
Chest discomfort | 27.70 | 18.45 | 54 | 73197 | 124327 | 70730866 |
Hyperkalaemia | 27.64 | 18.45 | 42 | 73209 | 106549 | 70748644 |
Drug level increased | 27.08 | 18.45 | 3 | 73248 | 36466 | 70818727 |
Blood pressure increased | 26.81 | 18.45 | 102 | 73149 | 188415 | 70666778 |
Muscle injury | 26.58 | 18.45 | 4 | 73247 | 38490 | 70816703 |
Pancreatitis | 26.38 | 18.45 | 16 | 73235 | 62652 | 70792541 |
Mucosal inflammation | 26.29 | 18.45 | 19 | 73232 | 67831 | 70787362 |
Metabolic acidosis | 26.08 | 18.45 | 23 | 73228 | 74323 | 70780870 |
Osteoporosis | 26.00 | 18.45 | 9 | 73242 | 48898 | 70806295 |
Irritable bowel syndrome | 25.94 | 18.45 | 10 | 73241 | 50840 | 70804353 |
Pneumocystis jirovecii pneumonia | 25.81 | 18.45 | 79 | 73172 | 30003 | 70825190 |
Cardio-respiratory arrest | 25.79 | 18.45 | 40 | 73211 | 100637 | 70754556 |
Abdominal discomfort | 25.71 | 18.45 | 124 | 73127 | 214534 | 70640659 |
Localised infection | 25.64 | 18.45 | 84 | 73167 | 33074 | 70822119 |
Wheezing | 25.50 | 18.45 | 36 | 73215 | 94134 | 70761059 |
Depressed mood | 25.20 | 18.45 | 7 | 73244 | 43813 | 70811380 |
Dysarthria | 24.74 | 18.45 | 17 | 73234 | 62296 | 70792897 |
Liver injury | 24.66 | 18.45 | 6 | 73245 | 41029 | 70814164 |
Epilepsy | 24.66 | 18.45 | 5 | 73246 | 38779 | 70816414 |
Ill-defined disorder | 24.44 | 18.45 | 13 | 73238 | 54728 | 70800465 |
Seizure | 24.22 | 18.45 | 98 | 73153 | 177864 | 70677329 |
Blister | 23.84 | 18.45 | 42 | 73209 | 100484 | 70754709 |
Bradycardia | 23.71 | 18.45 | 59 | 73192 | 124556 | 70730637 |
Dysphagia | 23.42 | 18.45 | 51 | 73200 | 112783 | 70742410 |
Migraine | 23.40 | 18.45 | 24 | 73227 | 72214 | 70782979 |
General physical health deterioration | 22.99 | 18.45 | 146 | 73105 | 235885 | 70619308 |
Neoplasm progression | 22.90 | 18.45 | 9 | 73242 | 45219 | 70809974 |
Clavicle fracture | 22.85 | 18.45 | 24 | 73227 | 3880 | 70851313 |
Injection site swelling | 22.84 | 18.45 | 8 | 73243 | 43149 | 70812044 |
Upper limb fracture | 22.76 | 18.45 | 51 | 73200 | 16068 | 70839125 |
Feeling hot | 22.56 | 18.45 | 11 | 73240 | 48659 | 70806534 |
Coronary artery disease | 22.50 | 18.45 | 19 | 73232 | 62717 | 70792476 |
Respiratory arrest | 22.38 | 18.45 | 14 | 73237 | 53919 | 70801274 |
Colitis ulcerative | 22.36 | 18.45 | 4 | 73247 | 33919 | 70821274 |
Restlessness | 21.97 | 18.45 | 8 | 73243 | 42120 | 70813073 |
Leukocytosis | 21.61 | 18.45 | 7 | 73244 | 39661 | 70815532 |
Generalised tonic-clonic seizure | 21.58 | 18.45 | 8 | 73243 | 41653 | 70813540 |
Spinal fracture | 21.55 | 18.45 | 50 | 73201 | 16117 | 70839076 |
Product quality issue | 21.51 | 18.45 | 3 | 73248 | 30558 | 70824635 |
Pulmonary arterial hypertension | 21.39 | 18.45 | 4 | 73247 | 32851 | 70822342 |
Accidental overdose | 21.37 | 18.45 | 5 | 73246 | 35116 | 70820077 |
Clostridium difficile infection | 21.30 | 18.45 | 88 | 73163 | 38728 | 70816465 |
Peritonitis viral | 21.21 | 18.45 | 6 | 73245 | 57 | 70855136 |
Coronavirus infection | 21.02 | 18.45 | 29 | 73222 | 6223 | 70848970 |
Hypersensitivity | 20.95 | 18.45 | 145 | 73106 | 229667 | 70625526 |
Swelling face | 20.90 | 18.45 | 124 | 73127 | 63040 | 70792153 |
Septic shock | 20.83 | 18.45 | 192 | 73059 | 112066 | 70743127 |
Listeriosis | 20.66 | 18.45 | 17 | 73234 | 2015 | 70853178 |
Dehydration | 20.57 | 18.45 | 338 | 72913 | 225804 | 70629389 |
Blood bilirubin increased | 20.45 | 18.45 | 19 | 73232 | 59882 | 70795311 |
Musculoskeletal pain | 20.29 | 18.45 | 39 | 73212 | 90288 | 70764905 |
Nausea | 20.26 | 18.45 | 699 | 72552 | 851389 | 70003804 |
Viral infection | 20.25 | 18.45 | 86 | 73165 | 38305 | 70816888 |
Hemiparesis | 20.13 | 18.45 | 4 | 73247 | 31465 | 70823728 |
Atelectasis | 20.02 | 18.45 | 3 | 73248 | 28959 | 70826234 |
Atrial flutter | 19.95 | 18.45 | 56 | 73195 | 20271 | 70834922 |
Off label use | 19.94 | 18.45 | 600 | 72651 | 742460 | 70112733 |
Light chain analysis decreased | 19.85 | 18.45 | 4 | 73247 | 6 | 70855187 |
Transaminases increased | 19.79 | 18.45 | 12 | 73239 | 47006 | 70808187 |
Flushing | 19.78 | 18.45 | 34 | 73217 | 82138 | 70773055 |
Gastrointestinal haemorrhage | 19.76 | 18.45 | 74 | 73177 | 137334 | 70717859 |
Arthropathy | 19.56 | 18.45 | 84 | 73167 | 149973 | 70705220 |
Unresponsive to stimuli | 19.53 | 18.45 | 15 | 73236 | 51916 | 70803277 |
Neutrophil count abnormal | 19.52 | 18.45 | 20 | 73231 | 3141 | 70852052 |
Osteolysis | 19.47 | 18.45 | 21 | 73230 | 3498 | 70851695 |
Meningitis listeria | 19.38 | 18.45 | 12 | 73239 | 908 | 70854285 |
Protein total increased | 19.29 | 18.45 | 21 | 73230 | 3536 | 70851657 |
Hip arthroplasty | 19.16 | 18.45 | 3 | 73248 | 28037 | 70827156 |
Anaphylactic shock | 19.04 | 18.45 | 5 | 73246 | 32485 | 70822708 |
Avulsion fracture | 18.96 | 18.45 | 8 | 73243 | 268 | 70854925 |
Shock | 18.95 | 18.45 | 9 | 73242 | 40416 | 70814777 |
Eosinophilia | 18.86 | 18.45 | 9 | 73242 | 40310 | 70814883 |
Compression fracture | 18.83 | 18.45 | 27 | 73224 | 6004 | 70849189 |
Pulmonary fibrosis | 18.78 | 18.45 | 6 | 73245 | 34304 | 70820889 |
Gastrointestinal disorder | 18.47 | 18.45 | 52 | 73199 | 105375 | 70749818 |
None
Source | Code | Description |
---|---|---|
ATC | L04AX06 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Other immunosuppressants |
MeSH PA | D020533 | Angiogenesis Inhibitors |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D006131 | Growth Inhibitors |
MeSH PA | D006133 | Growth Substances |
MeSH PA | D007155 | Immunologic Factors |
FDA EPC | N0000184014 | Thalidomide Analog |
CHEBI has role | CHEBI:35610 | antineoplastic agents |
CHEBI has role | CHEBI:48422 | angiogenesis antagonist |
CHEBI has role | CHEBI:50846 | Immunologic factor |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Multiple myeloma | indication | 109989006 | DOID:9538 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 7.84 | acidic |
pKa2 | 1.86 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
1MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | 8673939 | May 15, 2023 | USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA |
1MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | 8673939 | May 15, 2023 | USE OF POMALIDOMIDE WITH DEXAMETHASONE FOR PATIENTS WITH MULTIPLE MYELOMA AFTER AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR AND DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETING THE LAST THERAPY |
1MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | 8735428 | May 15, 2023 | USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA |
1MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | 8735428 | May 15, 2023 | USE OF POMALIDOMIDE WITH DEXAMETHASONE FOR PATIENTS WITH MULTIPLE MYELOMA AFTER AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR AND DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETING THE LAST THERAPY |
2MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | 8673939 | May 15, 2023 | USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA |
2MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | 8673939 | May 15, 2023 | USE OF POMALIDOMIDE WITH DEXAMETHASONE FOR PATIENTS WITH MULTIPLE MYELOMA AFTER AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR AND DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETING THE LAST THERAPY |
2MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | 8735428 | May 15, 2023 | USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA |
2MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | 8735428 | May 15, 2023 | USE OF POMALIDOMIDE WITH DEXAMETHASONE FOR PATIENTS WITH MULTIPLE MYELOMA AFTER AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR AND DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETING THE LAST THERAPY |
3MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | 8673939 | May 15, 2023 | USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA |
3MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | 8673939 | May 15, 2023 | USE OF POMALIDOMIDE WITH DEXAMETHASONE FOR PATIENTS WITH MULTIPLE MYELOMA AFTER AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR AND DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETING THE LAST THERAPY |
3MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | 8735428 | May 15, 2023 | USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA |
3MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | 8735428 | May 15, 2023 | USE OF POMALIDOMIDE WITH DEXAMETHASONE FOR PATIENTS WITH MULTIPLE MYELOMA AFTER AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR AND DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETING THE LAST THERAPY |
4MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | 8673939 | May 15, 2023 | USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA |
4MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | 8673939 | May 15, 2023 | USE OF POMALIDOMIDE WITH DEXAMETHASONE FOR PATIENTS WITH MULTIPLE MYELOMA AFTER AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR AND DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETING THE LAST THERAPY |
4MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | 8735428 | May 15, 2023 | USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA |
4MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | 8735428 | May 15, 2023 | USE OF POMALIDOMIDE WITH DEXAMETHASONE FOR PATIENTS WITH MULTIPLE MYELOMA AFTER AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR AND DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETING THE LAST THERAPY |
1MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | 8198262 | June 17, 2025 | USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA |
1MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | 8198262 | June 17, 2025 | USE OF POMALIDOMIDE WITH DEXAMETHASONE FOR PATIENTS WITH MULTIPLE MYELOMA AFTER AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR AND DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETING THE LAST THERAPY |
2MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | 8198262 | June 17, 2025 | USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA |
2MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | 8198262 | June 17, 2025 | USE OF POMALIDOMIDE WITH DEXAMETHASONE FOR PATIENTS WITH MULTIPLE MYELOMA AFTER AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR AND DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETING THE LAST THERAPY |
3MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | 8198262 | June 17, 2025 | USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA |
3MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | 8198262 | June 17, 2025 | USE OF POMALIDOMIDE WITH DEXAMETHASONE FOR PATIENTS WITH MULTIPLE MYELOMA AFTER AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR AND DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETING THE LAST THERAPY |
4MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | 8198262 | June 17, 2025 | USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA |
4MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | 8198262 | June 17, 2025 | USE OF POMALIDOMIDE WITH DEXAMETHASONE FOR PATIENTS WITH MULTIPLE MYELOMA AFTER AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR AND DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETING THE LAST THERAPY |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
1MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | Nov. 20, 2023 | ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION |
2MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | Nov. 20, 2023 | ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION |
3MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | Nov. 20, 2023 | ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION |
4MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | Nov. 20, 2023 | ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION |
1MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | May 20, 2024 | PEDIATRIC EXCLUSIVITY |
2MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | May 20, 2024 | PEDIATRIC EXCLUSIVITY |
3MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | May 20, 2024 | PEDIATRIC EXCLUSIVITY |
4MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | May 20, 2024 | PEDIATRIC EXCLUSIVITY |
1MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | May 14, 2027 | FOR THE TREATMENT OF KAPOSI SARCOMA (KS) IN ADULT PATIENTS WHO ARE HIV-NEGATIVE |
1MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | May 14, 2027 | INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH AIDS-RELATED KAPOSI SARCOMA (KS) AFTER FAILURE OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) |
2MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | May 14, 2027 | FOR THE TREATMENT OF KAPOSI SARCOMA (KS) IN ADULT PATIENTS WHO ARE HIV-NEGATIVE |
2MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | May 14, 2027 | INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH AIDS-RELATED KAPOSI SARCOMA (KS) AFTER FAILURE OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) |
3MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | May 14, 2027 | FOR THE TREATMENT OF KAPOSI SARCOMA (KS) IN ADULT PATIENTS WHO ARE HIV-NEGATIVE |
3MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | May 14, 2027 | INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH AIDS-RELATED KAPOSI SARCOMA (KS) AFTER FAILURE OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) |
4MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | May 14, 2027 | FOR THE TREATMENT OF KAPOSI SARCOMA (KS) IN ADULT PATIENTS WHO ARE HIV-NEGATIVE |
4MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | May 14, 2027 | INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH AIDS-RELATED KAPOSI SARCOMA (KS) AFTER FAILURE OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) |
1MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | Nov. 14, 2027 | PEDIATRIC EXCLUSIVITY |
2MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | Nov. 14, 2027 | PEDIATRIC EXCLUSIVITY |
3MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | Nov. 14, 2027 | PEDIATRIC EXCLUSIVITY |
4MG | POMALYST | CELGENE | N204026 | Feb. 8, 2013 | RX | CAPSULE | ORAL | Nov. 14, 2027 | PEDIATRIC EXCLUSIVITY |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Protein cereblon | Cytosolic other | MODULATOR | EC50 | 6.58 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
Cereblon isoform 4 | Unclassified | Ki | 6.10 | CHEMBL |
ID | Source |
---|---|
D08976 | KEGG_DRUG |
4032092 | VANDF |
CHEBI:72690 | CHEBI |
CHEMBL43452 | ChEMBL_ID |
C467566 | MESH_SUPPLEMENTAL_RECORD_UI |
7348 | IUPHAR_LIGAND_ID |
8873 | INN_ID |
DB08910 | DRUGBANK_ID |
D2UX06XLB5 | UNII |
1369713 | RXNORM |
199372 | MMSL |
29234 | MMSL |
d08041 | MMSL |
014897 | NDDF |
703789000 | SNOMEDCT_US |
703790009 | SNOMEDCT_US |
C2347624 | UMLSCUI |
134780 | PUBCHEM_CID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Pomalyst | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59572-501 | CAPSULE | 1 mg | ORAL | NDA | 32 sections |
Pomalyst | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59572-501 | CAPSULE | 1 mg | ORAL | NDA | 32 sections |
Pomalyst | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59572-502 | CAPSULE | 2 mg | ORAL | NDA | 32 sections |
Pomalyst | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59572-502 | CAPSULE | 2 mg | ORAL | NDA | 32 sections |
Pomalyst | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59572-503 | CAPSULE | 3 mg | ORAL | NDA | 32 sections |
Pomalyst | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59572-503 | CAPSULE | 3 mg | ORAL | NDA | 32 sections |
Pomalyst | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59572-504 | CAPSULE | 4 mg | ORAL | NDA | 32 sections |
Pomalyst | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59572-504 | CAPSULE | 4 mg | ORAL | NDA | 32 sections |